Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 23099358)

1.

Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure.

Frommeyer G, Schmidt M, Clauß C, Kaese S, Stypmann J, Pott C, Eckardt L, Milberg P.

Eur J Heart Fail. 2012 Dec;14(12):1322-31. doi: 10.1093/eurjhf/hfs163. Epub 2012 Oct 25.

PMID:
23099358
2.

Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.

Milberg P, Frommeyer G, Ghezelbash S, Rajamani S, Osada N, Razvan R, Belardinelli L, Breithardt G, Eckardt L.

Europace. 2013 May;15(5):761-9. doi: 10.1093/europace/eus399. Epub 2013 Feb 1.

3.

New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia.

Frommeyer G, Rajamani S, Grundmann F, Stypmann J, Osada N, Breithardt G, Belardinelli L, Eckardt L, Milberg P.

J Card Fail. 2012 Dec;18(12):939-49. doi: 10.1016/j.cardfail.2012.10.017.

PMID:
23207083
4.

Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.

Frommeyer G, Milberg P, Uphaus T, Kaiser D, Kaese S, Breithardt G, Eckardt L.

Cardiovasc Ther. 2013 Dec;31(6):e63-71. doi: 10.1111/1755-5922.12035.

PMID:
23647657
5.

Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits.

Aidonidis I, Doulas K, Hatziefthimiou A, Tagarakis G, Simopoulos V, Rizos I, Tsilimingas N, Molyvdas PA.

J Cardiovasc Pharmacol Ther. 2013 Jan;18(1):94-101. doi: 10.1177/1074248412453874. Epub 2012 Aug 7.

PMID:
22872232
6.

Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.

Burashnikov A, Di Diego JM, Barajas-Martínez H, Hu D, Zygmunt AC, Cordeiro JM, Moise NS, Kornreich BG, Belardinelli L, Antzelevitch C.

Circ Heart Fail. 2014 Jul;7(4):627-33. doi: 10.1161/CIRCHEARTFAILURE.114.001129. Epub 2014 May 29.

7.

Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.

Kumar K, Nearing BD, Carvas M, Nascimento BC, Acar M, Belardinelli L, Verrier RL.

J Cardiovasc Electrophysiol. 2009 Jul;20(7):796-802. doi: 10.1111/j.1540-8167.2009.01437.x. Epub 2009 Feb 27.

PMID:
19298570
8.

A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure.

Frommeyer G, Milberg P, Witte P, Stypmann J, Koopmann M, Lücke M, Osada N, Breithardt G, Fehr M, Eckardt L.

Eur J Heart Fail. 2011 Oct;13(10):1060-9. doi: 10.1093/eurjhf/hfr107. Epub 2011 Aug 25.

PMID:
21873342
9.

Effects of Cilazapril on atrial electrical, structural and functional remodeling in atrial fibrillation dogs.

Li Y, Li W, Yang B, Han W, Dong D, Xue J, Li B, Yang S, Sheng L.

J Electrocardiol. 2007 Jan;40(1):100.e1-6. Epub 2006 Oct 25.

PMID:
17067622
10.

G-CSF therapy reduces myocardial repolarization reserve in the presence of increased arteriogenesis, angiogenesis and connexin 43 expression in an experimental model of pacing-induced heart failure.

Milberg P, Klocke R, Frommeyer G, Quang TH, Dieks K, Stypmann J, Osada N, Kuhlmann M, Fehr M, Milting H, Nikol S, Waltenberger J, Breithardt G, Eckardt L.

Basic Res Cardiol. 2011 Nov;106(6):995-1008. doi: 10.1007/s00395-011-0230-8. Epub 2011 Nov 10.

PMID:
22072114
11.

Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.

Milberg P, Tegelkamp R, Osada N, Schimpf R, Wolpert C, Breithardt G, Borggrefe M, Eckardt L.

J Cardiovasc Electrophysiol. 2007 Jun;18(6):658-64.

PMID:
17521304
12.

Ranolazine terminates atrial flutter and fibrillation in a canine model.

Bhimani AA, Yasuda T, Sadrpour SA, Khrestian CM, Lee S, Zeng D, Belardinelli L, Waldo AL.

Heart Rhythm. 2014 Sep;11(9):1592-9. doi: 10.1016/j.hrthm.2014.05.038. Epub 2014 Jun 2.

PMID:
25066042
13.

Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits.

Frommeyer G, Kaiser D, Uphaus T, Kaese S, Osada N, Rajamani S, Belardinelli L, Breithardt G, Eckardt L, Milberg P.

Heart Rhythm. 2012 Dec;9(12):2051-8. doi: 10.1016/j.hrthm.2012.08.029. Epub 2012 Aug 28.

PMID:
23044390
14.

Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.

Burashnikov A, Belardinelli L, Antzelevitch C.

J Pharmacol Exp Ther. 2012 Jan;340(1):161-8. doi: 10.1124/jpet.111.186395. Epub 2011 Oct 17.

15.

Vernakalant in an experimental model of pacing-induced heart failure: lack of proarrhythmia despite prolongation of repolarization.

Frommeyer G, Schulze Grotthoff J, Fischer C, Bogossian H, Reinke F, Kochhäuser S, Dechering DG, Fehr M, Milberg P, Eckardt L.

J Card Fail. 2014 Oct;20(10):786-92. doi: 10.1016/j.cardfail.2014.07.013. Epub 2014 Jul 30.

PMID:
25084217
16.

Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Li D, Fareh S, Leung TK, Nattel S.

Circulation. 1999 Jul 6;100(1):87-95.

17.

Chronic myocardial infarction promotes atrial action potential alternans, afterdepolarizations, and fibrillation.

Kettlewell S, Burton FL, Smith GL, Workman AJ.

Cardiovasc Res. 2013 Jul 1;99(1):215-24. doi: 10.1093/cvr/cvt087. Epub 2013 Apr 8.

18.

Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization.

Frommeyer G, Milberg P, Clauss C, Schmidt M, Ramtin S, Kaese S, Grundmann F, Grotthoff JS, Pott C, Eckardt L.

Europace. 2014 Aug;16(8):1240-8. doi: 10.1093/europace/euu014. Epub 2014 Apr 2.

19.

Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.

Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, Nattel S.

Circulation. 2007 Jan 23;115(3):310-8. Epub 2007 Jan 15.

20.

Repetitive electrical remodeling by paroxysms of atrial fibrillation in the goat: no cumulative effect on inducibility or stability of atrial fibrillation.

Garratt CJ, Duytschaever M, Killian M, Dorland R, Mast F, Allessie MA.

J Cardiovasc Electrophysiol. 1999 Aug;10(8):1101-8.

PMID:
10466491
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk